264 related articles for article (PubMed ID: 26729247)
21. Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells.
Joseph D; Gonsky JP; Blain SW
PLoS One; 2018; 13(11):e0206368. PubMed ID: 30383785
[TBL] [Abstract][Full Text] [Related]
22. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.
Akhmetzyanova I; McCarron MJ; Parekh S; Chesi M; Bergsagel PL; Fooksman DR
Leukemia; 2020 Jan; 34(1):245-256. PubMed ID: 31439945
[TBL] [Abstract][Full Text] [Related]
23. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
[TBL] [Abstract][Full Text] [Related]
24. [Detection of circulating and bone marrow myeloma cells in patients with multiple myeloma and its clinical significance].
Jiang YQ; Li JY; Wu YJ; Yang H; Shen YF; Chen LJ; Xu W; Qian SX; Wu HX; Lu H; Shen RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):908-12. PubMed ID: 17096887
[TBL] [Abstract][Full Text] [Related]
25. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
26. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
27. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
28. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma with CD138 changed from positive to negative: A case report.
Yu J; Tan L; Wu Q; Rao Y; Ao J; Yang W; Zou B; Chen J
Cytometry B Clin Cytom; 2021 Mar; 100(2):249-253. PubMed ID: 31967404
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.
Huhn S; Weinhold N; Nickel J; Pritsch M; Hielscher T; Hummel M; Bertsch U; Huegle-Doerr B; Vogel M; Angermund R; Hänel M; Salwender HJ; Weisel K; Dürig J; Görner M; Kirchner H; Peter N; Graeven U; Lordick F; Hoffmann M; Reimer P; Blau IW; Jauch A; Dembowsky K; Möhler T; Wuchter P; Goldschmidt H
Bone Marrow Transplant; 2017 Aug; 52(8):1194-1198. PubMed ID: 28504661
[No Abstract] [Full Text] [Related]
31. Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma.
Pugh TJ
Semin Hematol; 2018 Jan; 55(1):38-40. PubMed ID: 29759151
[TBL] [Abstract][Full Text] [Related]
32. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.
Colla S; Storti P; Donofrio G; Todoerti K; Bolzoni M; Lazzaretti M; Abeltino M; Ippolito L; Neri A; Ribatti D; Rizzoli V; Martella E; Giuliani N
Leukemia; 2010 Nov; 24(11):1967-70. PubMed ID: 20811474
[No Abstract] [Full Text] [Related]
33. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
Foulk B; Schaffer M; Gross S; Rao C; Smirnov D; Connelly MC; Chaturvedi S; Reddy M; Brittingham G; Mata M; Repollet M; Rojas C; Auclair D; DeRome M; ; Weiss B; Sasser AK
Br J Haematol; 2018 Jan; 180(1):71-81. PubMed ID: 29105742
[TBL] [Abstract][Full Text] [Related]
34. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
35. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
36. Stimulus-Responsive Microfluidic Interface Enables Efficient Enrichment and Cytogenetic Profiling of Circulating Myeloma Cells.
Liu Y; Su R; Song J; Yu X; Lin S; Zhu Z; Yang Y; Zhang M; Yang L; Zhang H; Xu X; Yang C
ACS Appl Mater Interfaces; 2021 Apr; 13(13):14920-14927. PubMed ID: 33755428
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
38. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
39. Metastatic hepatocellular carcinoma with CD138 positivity: an unusual mimic of multiple myeloma?
Ramalingam P; Adeagbo B; Bollag R; Lee J; Reid-Nicholson M
Diagn Cytopathol; 2008 Oct; 36(10):742-8. PubMed ID: 18773447
[TBL] [Abstract][Full Text] [Related]
40. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
